Methadone is a long-acting opioid with considerable unexplained interindividual variability in clearance. Cytochrome P4502B6 (CYP2B6) mediates clinical methadone clearance and metabolic inactivation via N-demethylation to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). Retrospective studies suggest that individuals with the CYP2B6*6 allelic variant have higher methadone plasma concentrations. Catalytic activities of CYP2B6 variants are highly substrate-and expression-system dependent. This investigation evaluated methadone N-demethylation by expressed human CYP2B6 allelic variants in an insect cell co-expression system containing P450 reductase. Additionally, the influence of co-expressing cytochrome b 5 , whose role in metabolism can be inhibitory or stimulatory, and dependent on the CYP isoform and substrate, on methadone metabolism was evaluated. These results show that methadone N-demethylation by CYP2B6.4 is greater compared with CYP2B6.1, while CYP2B6.9 and CYP2B6.6 (which both contain the 516G>T, Q172H polymorphism), are catalytically deficient. The presence or absence of b 5 in expression systems may explain previously reported disparate catalytic activities of CYP2B6 variants for specific substrates. Differences in methadone metabolism by CYP2B6 allelic variants provide a mechanistic understanding for pharmacogenetic variability in clinical methadone metabolism and clearance.
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Introduction
Methadone is a long-duration opioid used (primarily as a racemate) to treat multiple types of acute, chronic, and cancer pain, as well as opiate addiction. Methadone use, particularly for pain, has grown exponentially over the past decades. However, the incidence of unanticipated methadone toxicity, and related fatalities, has grown disproportionately, even more so than the increase in methadone use (Paulozzi et al., 2012) . There is considerable inter-and intra-individual variability in constitutive methadone metabolism and clearance, and also susceptibility to drug interactions, with the greatest risk related to unanticipated accumulation (Ferrari et al., 2004; Bruce et al., 2013) . Variable disposition complicates the clinical use of methadone, and, despite considerable research, mechanisms of variability remain insufficiently understood.
Hepatic methadone N-demethylation to the inactive metabolite 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) is the major route of systemic clearance. Both methadone clearance and Ndemethylation are stereoselective. Methadone N-demethylation in vitro, by human liver microsomes and by expressed cytochrome P450s (CYPs), is catalyzed most efficiently by CYP2B6 and CYP3A4, and only CYP2B6 N-demethylates methadone stereoselectively (S>R) (Gerber et al., 2004; Kharasch et al., 2004; Totah et al., 2007; Totah et al., 2008; Chang et al., 2011; Gadel et al., 2013) . Although both CYPs metabolize methadone in vitro, it has become clear that CYP2B6, rather than CYP3A4, is the predominant CYP responsible for clinical methadone disposition. Evidence derives from drug interaction and genetic studies (Greenblatt, 2014) . CYP2B6 induction or inhibition correspondingly modulated methadone metabolism, clearance, and plasma concentrations (Kharasch et al., 2004; Kharasch et al., 2008a; Kharasch et al., 2008b; Kharasch and Stubbert, 2013b) . In contrast, strong CYP3A inhibitors (Kharasch et al., 2004; Kharasch et al., 2008a; van Heeswijk et al., 2011; Kharasch et al., 2012; Kharasch and Stubbert, 2013a) failed to diminish (and sometimes increased) methadone N-demethylation and clearance, and CYP3A induction also had no effect (Vourvahis et al., 2012) . CYP2B6 polymorphisms may influence clinical methadone disposition. Gene-association studies suggested that the CYP2B6*6 polymorphism was associated with higher dose-adjusted steady-state plasma methadone concentrations This article has not been copyedited and formatted. The final version may differ from this version. (Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007; Wang et al., 2011) or use of lower methadone doses (Hung et al., 2011; Levran et al., 2011) . Methadone N-demethylation and clearance were greater and lesser than wild-types, respectively, in CYP2B6*4 and CYP2B6*6 carriers (Kharasch et al., 2014) .
Whereas the fraction of total hepatic CYP represented by CYP2B6 is small, it nonetheless metabolizes a disproportionately greater percentage of drugs (Wang and Tompkins, 2008; Mo et al., 2009 ). The CYP2B6 gene is highly polymorphic , with thirty-eight CYP2B6 protein variants identified to date (http://www.cypalleles.ki.se/cyp2b6.htm). The functional consequences of CYP2B6 allelic variants on catalytic activity in vitro are allele, substrate, and expression systemdependent (Turpeinen and Zanger, 2012; Zanger and Klein, 2013) . CYP function can also be influenced (or not) by co-expression of cytochrome b 5 (Xu et al., 2012) , and allelic variant effects in vivo are additionally influenced by quantitative differences in CYP2B6 protein expression (Turpeinen and Zanger, 2012; Zanger and Klein, 2013) . Among the more well studied variants, CYP2B6*4 (785A>G, K262R) is described as causing increased expression and variably increased or decreased enzymatic activity, CYP2B6*5 (1459C>T, R487C) causing decreased expression and increased specific activity, CYP2B6*6 (516G>T, Q172H; 785A>G, K262R) causing markedly reduced expression and substrate-dependent changes in activity, CYP2B6*18 (983T>C, I328T) having reduced expression and activity (Turpeinen and Zanger, 2012; Zanger and Klein, 2013) . The CYP2B6*6 allele is of particular interest, due to its frequent occurrence (particularly in African, Asian, and Hispanic populations) and therapeutic significance towards the metabolism, pharmacokinetics, and clinical effects of efavirenz, cyclophosphamide, and bupropion (Turpeinen and Zanger, 2012; Zanger and Klein, 2013) . We recently reported that methadone N-demethylation catalyzed by CYP2B6.6, the CYP2B6 variant encoded by the CYP2B6*6 polymorphism, is catalytically deficient compared with wild-type CYP2B6.1, and, that human liver microsomes with diminished CYP2B6 content due to a CYP2B6*6 allele had lower rates of methadone Ndemethylation (Gadel et al., 2013) .
The purpose of the present investigation was to further characterize methadone N-demethylation by CYP2B6 allelic variants, including CYP2B6.1, CYP2B6.4, CYP2B6.5, CYP2B6.6, CYP2B6.9 and This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Chemicals and Reagents. EDDP and EDDP-d3 were purchased from Cerilliant (Round Rock, TX). Rand S-methadone were from NIDA (Bethesda, MD). All other reagents were from Sigma-Aldrich (St.
Louis, MO).
Construction of Plasmids. Human CYP2B6, P450 reductase (POR), and cytochrome b 5 were PCR amplified from the Human Liver QUICK-Clone cDNA library (Clontech, Mountain View, CA). CYP2B6 variants (2B6.4, 2B6.5, 2B6.6, 2B6.9, 2B6.18) were made from CYP2B6.1 DNA using the QuickChange XL Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA). CYP2B6, POR, and b 5 DNA was individually inserted into the pVL1393 vector using the In-Fusion HD Cloning System (Clontech, Mountain View, CA). All sequences were verified by the Protein and Nucleic Acid Chemistry Laboratory (PNACL) at Washington University in St. Louis. visualized using an Odyssey Infrared Imager (Li-Cor, Lincoln, NE) . P450 concentration was determined as previously described with minor modifications (Matsubara et al., 1976) . Briefly, cell lysate was diluted to 1 mg/ml and bubbled with CO and the baseline absorbance reading was taken from 400-500 nm using a SynergyMX plate reader (Biotek, Winooski, VT). Sodium dithionite (final concentration 25 mM) was added immediately after obtaining the reference baseline and the final absorbance reading was taken after 2 min. Cytochrome c reductase activity was determined using 0.3 M potassium phosphate buffer (pH 7.7) at 37°C (Dignam and Strobel, 1977) using the SynergyMX plate reader. Cytochrome b 5 content was determined as previously described (McLaughlin et al., 2010) . The CYP:reductase ratio was calculated based on an assumed specific activity of 3200 nmol cytochrome c reduced/min/nmol reductase (Parikh et al., 1997) .
Generation of
Methadone Metabolism. Incubations (200 μl) with R-or S-methadone were performed as previously described (Gadel et al., 2013) , with minor modifications. Preliminary experiments showed that Ndemethylation was linear for up to 45 min; routine incubations were 10 min. Reactions (10 min) were quenched with 40 µl 20% trichloroacetic acid containing internal standard (d3-EDDP, final concentration 1.6 ng/ml and centrifuged for 5 min at 2500 g; the supernatant (150 µl) was processed immediately by solid-phase extraction as described previously (Kharasch et al., 2004) , except that Strata-X-C 33µm, 30 mg/well plates (Phenomenex, Torrance, CA) were used. EDDP and methadone achiral analysis was performed on an Agilent 6140 single quadrupole mass spectrometer with an electrospray ionization source, Agilent 1100 series high-pressure liquid chromatography system equipped with a 96-well plate autosampler (Agilent Technologies, Inc., Santa Clara, CA), and a Sunfire C18 column (2.1 x 50 mm, 3.5 µm) (Waters, Milford, MA) with a 2 µm column filter guard (Supleco Analytical, Bellefonte, PA).
Sample injections were 25 µl and the column oven was held at 30°C. Mobile phase A was 4.5 mM ammonium acetate in milli Q water, pH 4.5 and mobile phase B was 4.5 mM ammonium acetate in acetonitrile. The mobile phase (0.4 ml/min) gradient was 25% B for 0. Mass spectrometer parameters were: positive ion mode, nitrogen drying gas at 12 L/min and 300°C, nebulizer pressure of 35 psig, capillary voltage 3000 V and fragmentor voltage of 80 V for EDDP 70 V for d3-EDDP. All ions were monitored in the same ion group: m/z of 278.2 and 281.2 for EDDP and d3-EDDP, respectively. Analytes were quantified using peak area ratios and standard curves prepared using calibration standards in buffer. Control incubations lacking enzyme were included for all reactions to determine background EDDP content, which was subtracted from all results.
Data and Statistical Analysis. Results are the mean ± SD (3-6 replicates) unless otherwise indicated.
EDDP formation by CYP2B6 variants was compared by analysis of variance. EDDP formation vs substrate concentration data were analyzed by nonlinear regression analysis (SigmaPlot 12.5, Systat, San
Jose, CA) evaluating a single-enzyme Michaelis-Menten, Adair Pauling, or substrate (or product inhibition) model as described previously (Totah et al., 2007; Totah et al., 2008; Gadel et al., 2013) . The choice of model was based on whether the Eadie-Hofstee plots were linear or non-linear and the goodness of fit regression diagnostics. Modeling results are the parameter estimate ± standard error of the estimate.
Parameter estimates for CYP2B6 variants and CYP2B1.1 were compared using an unpaired t-test.
Significance was assigned at p<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. CYP content, P450 reductase activity, and b 5 content of the various constructs are provided in Table 1 .
Methadone enantiomers N-demethylation was evaluated at plasma concentrations (0.25-1 µM)
typically occurring in patients receiving low and high doses of methadone, respectively, for treatment of The concentration-dependence of methadone enantiomers N-demethylation was determined both in the presence and absence of co-expressed cytochrome b 5 for CYP2Bs 6.1, 6.4, 6.5, 6.6, and 6.9 ( Figure   3 ). There was evidence for substrate or product inhibition at the highest concentration of S-methadone (but not R-methadone), as observed previously (Gadel et al., 2013) . Eadie-Hosfstee plots were generally linear, with or without co-expressed b 5 (not shown). Linear plots were interpreted as methadone binding to a single site, and analyzed with the Michaelis-Menten model, with substrate inhibition where apparent.
Kinetic parameters are provided in Table 2 . 
Discussion
The major finding was that at therapeutic concentrations, N-demethylation of R-and Smethadone by the variant CYP2B6 isoform CYP2B6.4 was greater than that by wild-type CYP2B6.1, while EDDP formation by CYP2B6.6 and CYP2B6.9 was less than CYP2B6.1, and CYP2B6.18 was catalytically incompetent. Assessed over broader methadone concentrations, in vitro intrinsic clearances for CYP2B6.6 and CYP2B6.9 were significantly lower than for CYP2B6.1. Stereoselectivity of methadone metabolism was maintained in all CYP2B6 variants, with S-methadone N-demethylation 2-fold greater than that of R-methadone, similar to that with CYP2B6.1 (Gerber et al., 2004; Totah et al., 2007; Totah et al., 2008; Chang et al., 2011; Gadel et al., 2013) . Lower rates of CYP2B6.6-catalyzed methadone N-demethylation in the present investigation, in which insect cells were transfected with individual virus constructs for CYP2B6, P450 reductase, and cytochrome b 5 , were also seen in an insect cell system transfected with a single virus containing all three proteins (Gadel et al., 2013) .
The kinetics of methadone N-demethylation by CYP2B6 are complex (Totah et al., 2007; Gadel et al., 2013) . Previous experiments with expressed CYP2B6.1 and CYP2B6.6 suggested apparent multisite or multiple-affinity methadone binding with complex allosteric kinetics or homotropic cooperativity, modeled best using the Adair-Pauling equation (Totah et al., 2007; Gadel et al., 2013) . Although there appeared to be substrate or product inhibition with CYP2B6.6 at the highest S-methadone concentration, this could not be modeled (Gadel et al., 2013) . In the present investigation, substrate (or product) inhibition with S-methadone was more apparent, and more amenable to modeling, and Michaelis-Menten kinetics with substrate inhibition provided better fits to the data. Nonetheless, differences between kinetic models did not materially affect the intrinsic clearances or conclusions of this investigation, that metabolism by CYP2B6.4 was greater than by CYP2B6.1, CYP2B6.5 was lower, and CYP2B6.6 and CYP2B6.9 were substantially less.
CYP2B6 expression levels in the triple protein constructs differed between allelic variants, resulting in varying CYP:P450 reductase molar ratios. Nonetheless, this did not explain the differences between variants in methadone metabolism. Such varying ratios were also seen previously, with (Xu et al., 2012; Gadel et al., 2013) . When reductase levels are sufficient for catalytic activity, overexpression of reductase may not be a factor (Nakajima et al., 2002) .
The influence of CYP2B6 allelic mutations on catalytic activity, in general, is CYP2B6 variantand substrate-dependent (Mo et al., 2009; Zanger and Klein, 2013) . In an insect cell system with coexpressed P450 reductase and b 5 , CYP2B6.6 Cl int for bupropion 4-hydroxylation was lower, while efavirenz 8-hydroxylation was less but not significantly different, than CYP2B6.1 (Xu et al., 2012 ).
CYP2B6.6 activity in other systems (E. Coli, Cos-1, Cos-7) was lower towards bupropion and efavirenz (Zhang et al., 2011) , and ketamine (Li et al., 2013) , but greater for cyclophosphamide (Xie et al., 2003; Ariyoshi et al., 2011; Raccor et al., 2012) and artemether (Honda et al., 2011) , and unchanged for selegiline (Watanabe et al., 2010) . The present and previous (Gadel et al., 2013) experiments show that methadone is one of the most catalytically diminished substrates for CYP2B6.6. A novel finding herein is that CYP2B6.9 is also catalytically deficient towards methadone. Data regarding the functional activity of CYP2B6.9 are said to be rare . In a COS-1 system, the activities of CYP2B6.6 and CYP2B6.9, in which 516G>T is the common polymorphism, were both extremely low, but this was attributed to minimal expression (Hofmann et al., 2008) . CYP2B6.9 activity towards artemether was somewhat lower than CYP2B6.1 in COS-7 cells (Honda et al., 2011) , and towards 7-ethoxy-4-trifluoromethylcoumarin, bupropion and efavirenz in a reconstituted bacterial expression system (Zhang et al., 2011) . The present results suggest that methadone is also one of the more catalytically diminished substrates with CYP2B6.9. Although CYP2B6.5 may be considered to have increased catalytic activity which compensates for lower expression , this was not observed with methadone. CYP2B6.5 activities are variable with other substrates. CYP2B6.5 cyclophosphamide 4-hydroxylation in E. Coli, Cos-1, and Cos-7 systems, was half that of CYP2B6.1 (Raccor et al., 2012) , and artemether and selegiline metabolism was diminished (Watanabe et al., 2010; Honda et al., 2011) , while 7-ethoxy-4-trifluoromethylcoumarin, bupropion, and efavirenz metabolism was decreased by one-third, half, and increased, respectively, compared to CYP2B6.1 (Zhang et al., 2011;  This article has not been copyedited and formatted. The final version may differ from this version. systems, CYP2B6.4 cyclophosphamide 4-hydroxylation was 25% lower than CYP2B6.1 (Ariyoshi et al., 2011; Raccor et al., 2012) , the catalytic efficiency for 7-ethoxy-4-trifluoromethylcoumarin, bupropion, and efavirenz was decreased to half, one-third, and unchanged, respectively (Zhang et al., 2011) , and artemether and selegiline metabolism was almost doubled (Watanabe et al., 2010; Honda et al., 2011) .
Methadone metabolism by CYP2B6.4 in the present investigation was greater than by CYP2B6.1. Thus, while 785A>G (K262R) alone (CYP2B6.4) caused increased methadone N-demethylation, 785A>G
together with 516G>T (Q172H) (CYP2B6.6), and 516G>T alone (CYP2B6.9) diminished methadone metabolism. Catalytic incompetence of CYP2B6.18 towards methadone is consistent with other CYP2B6
substrates .
The influence of CYP2B6 allelic mutations on catalytic activity appears dependent on the enzyme system used. In addition to differences noted above between various expression systems, most have also polymorphisms . This investigation appears to be one of the first to use an insect cell system with a panel of CYP2B6 variants and co-expressed P450 reductase and b 5 . Use of fully competent CYP2B6 systems, containing both P450 reductase and cytochrome b 5 , may be advantageous.
Although the present investigation evaluated only catalytic activity, some clinical implications can be inferred regarding the influence of CYP2B6 variants on methadone disposition. Clinical consequences of CYP2B6 allelic variants will depend on both the intrinsic activity of the mutant protein and its level of expression. The CYP2B6*6 allele causes low human hepatic CYP2B expression (Lang et al., 2001; Desta et al., 2007; Hofmann et al., 2008) , thus both deficient catalytic efficiency and decreased This article has not been copyedited and formatted. The final version may differ from this version. Liver microsomes from CYP2B6*6 carriers had diminished methadone N-demethylation (Gadel et al., 2013) . The lower CYP2B6.9 and CYP2B6.18 activities towards methadone suggest that similar results might be expected with CYP2B6*9 and CYP2B6*18 carriers, however microsomal methadone metabolism by livers from carriers of variants other than CYP2B6*6 have not been reported. Clinical genetic association studies of methadone plasma concentrations are consistent with diminished methadone N-demethylation by CYP2B6.6 and liver microsomes from CYP2B6*6 carriers. In patients, methadone doses were lower (Hung et al., 2011; Levran et al., 2011) , and dose-adjusted steady-state Smethadone concentrations were greater (Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007; Wang et al., 2011) , in CYP2B6*6 homozygotes compared with heterozygotes and non-carriers. While these observations suggested that CYP2B6 allelic variants might influence clinical methadone pharmacokinetics, only recently has this been confirmed. Methadone enantiomers N-demethylation and clearance were increased, and decreased, respectively, in CYP2B6*4 and CYP2B6*6 carriers (Kharasch et al., 2014) . Thus in vitro methadone metabolism by CYP2B6 variants does predict clinical methadone metabolism and clearance.
An interesting finding is that b 5 co-expression influenced methadone metabolism, and this was CYP2B6 variant-specific. Co-expression of b 5 stimulated R-and S-methadone metabolism by CYP2B6.1, CYP2B6.4, and CYP2B6.5, with less or minimal effects on CYP2B6.6 and CYP2B6.9. In the CYP catalytic cycle, involving two sequential one-electron transfers from NADPH to CYP and substrate, P450 reductase transfers the first electron, while the second electron may be transferred by P450 reductase or by b 5 (Hildebrandt and Estabrook, 1971; Schenkman and Jansson, 2003) . Effects of b 5
are however variable, stimulating, inhibiting, or not affecting metabolism, depending on the CYP isoform, substrate, and experimental conditions (Schenkman and Jansson, 2003l; Finn et al., 2008; Im and Waskell, 2011) . Recently this variability was shown for the first time to extend to CYP variants, with some CYP1A2 mutants quite affected by b 5 (Palma et al., 2013) . and Lys139, which were important for CYP2B4 binding to b 5 , are thought to perturb the C-helix, and R422 also affected CYP2B4 binding (Ahuja et al., 2013) . Based on sequence alignments, the CYP2B4 residues Arg122, Arg126, Met137, Lys139, and Arg422, which influence binding to b 5 , correspond to Lys122, Arg126, Met137, Lys139, and Lys422 of CYP2B6. The mutated residues in CYP2B6.6 (Gln172His, Lys262Arg), however do not correspond to the b 5 binding site identified on CYP2B4. With CYP1A2, the variant Gly299Ser (CYP1A2.13) had the most altered b 5 response compared with wild-type, with a lesser influence of the variants Thr83Met (CYP1A2.9), Ile386Phe (CYP1A2.4) and Cys406Tyr
(CYP1A2.5) (Palma et al., 2013) . Gly299Ser was reported to be on the surface of the heme domain near the interaction site with b 5 , and close to the CYP1A2 C-helix, which is also thought to be important in interaction with b 5 (Palma et al., 2013) . Based on sequence alignment of CYP2B6 with CYP1A2, Thr83, Gly299, Ile386, and Cys406 of CYP1A2 correspond to CYP2B6 Arg73, His280, Val367, and Ile387. Table 2 .
This article has not been copyedited and formatted. The final version may differ from this version. V max (pmol/min/pmol P450) 11 ± 1 9 ± 1 19 ± 1* 8 ± 1* 22 ± 4* 13 ± 5 4 ± 3* 2 ± 1* 7 ± 4 6 ± 4 K m (µM) 87 ± 4 48 ± 6 148 ± 6* 34 ± 3* 284 ± 73* 138 ± 78 337 ± 290 54 ± 46 298 ± 204 92 ± 91
Cl int (ml/min/nmol) 0.13 ± 0.01 0.19 ± 0.03 0.13 ± 0.01 0.23 ± 0.02 0.08 ± 0.03 0.09 ± 0.06 0.01 ± 0.01* 0.04± 0.04* 0.02± 0.02* 0.07± 0.08 CYP2B6 + P450 reductase V max (pmol/min/pmol P450) 5 ± 1 4 ± 1 9 ± 1* 7 ± 1* 5 ± 1 5 ± 1 2 ± 1* 4 ± 2 3 ± 1* 4 ± 2 
Figure 3
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